We are live on ! Find out more
VERV

Verve Therapeutics
VERV

Delisted

VERV was delisted on the 24th of July, 2025.

Back to rankings

134 hedge funds and large institutions have $847M invested in Verve Therapeutics in 2023 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 58 increasing their positions, 24 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

142% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 24

93% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 14

40% more call options, than puts

Call options by funds: $7M | Put options by funds: $4.99M

11% more funds holding

Funds holding: 121 → 134 (+13)

0.31% more ownership

Funds ownership: 99.94% → 100.25% (+0.31%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

27% less capital invested

Capital invested by funds: $1.16B → $847M (-$313M)

Holders
134
Holders Change
+13
Holders Change %
+10.74%
% of All Funds
2.13%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
27
Increased
58
Reduced
24
Closed
14
Calls
$7M
Puts
$4.99M
Net Calls
+$2M
Net Calls Change
+$1.64M

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$11.9M
2
JP Morgan Chase
JP Morgan Chase
New York
+$10.7M
3
CC
Casdin Capital
New York
+$9.57M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$8.55M
5
LGM
Logos Global Management
California
+$3.46M

Top Sellers

Rank Fund Capital Flow
1
APM
Avidity Partners Management
Texas
-$9.55M
2
NHAS
Novo Holdings A/S
Denmark
-$9.38M
3
Citadel Advisors
Citadel Advisors
Florida
-$7.39M
4
RG
Redmile Group
California
-$4.06M
5
PHS
PFM Health Sciences
California
-$3.49M
Name Holding Trade Value Shares
Change 		Change in
Stake
Royal Bank of Canada
76
Royal Bank of Canada
Ontario, Canada
$263K +$45.1K +2,801 +16%
Jane Street
77
Jane Street
New York
$262K -$1.05M -65,139 -77%
CIBC World Market
78
CIBC World Market
Ontario, Canada
$253K +$307K +19,048 New
SG Americas Securities
79
SG Americas Securities
New York
$248K +$301K +18,715 New
T. Rowe Price Associates
80
T. Rowe Price Associates
Maryland
$243K +$23.3K +1,447 +9%
Nomura Holdings
81
Nomura Holdings
Japan
$241K -$14.5K -900 -5%
AG
82
Algert Global
California
$239K – – –
PI
83
PEAK6 Investments
Illinois
$239K +$290K +18,000 New
Principal Financial Group
84
Principal Financial Group
Iowa
$223K +$41.3K +2,566 +18%
Mitsubishi UFJ Asset Management
85
Mitsubishi UFJ Asset Management
Japan
$219K +$14K +871 +6%
Janus Henderson Group
86
Janus Henderson Group
United Kingdom
$202K +$386 +24 +0.2%
State Board of Administration of Florida Retirement System
87
State Board of Administration of Florida Retirement System
Florida
$192K +$1.45K +90 +0.6%
EFM
88
E Fund Management
China
$191K +$24.1K +1,499 +12%
NSEDCP
89
NJ State Employees Deferred Compensation Plan
New Jersey
$186K – – –
XT
90
XTX Topco
Cayman Islands
$175K +$30.1K +1,872 +17%
ASRS
91
Arizona State Retirement System
Arizona
$164K +$17K +1,054 +9%
Teacher Retirement System of Texas
92
Teacher Retirement System of Texas
Texas
$160K +$18.9K +1,174 +11%
MFG
93
Merit Financial Group
Georgia
$151K +$184K +11,416 New
EAM
94
Erste Asset Management
Austria
$146K – – –
ProShare Advisors
95
ProShare Advisors
Maryland
$143K +$2.45K +152 +1%
PCM
96
Penserra Capital Management
California
$113K +$21.7K +1,350 +19%
Zurich Cantonal Bank
97
Zurich Cantonal Bank
Switzerland
$94.3K – – –
VEA
98
Virtus ETF Advisers
New York
$76.7K -$9.29K -577 -9%
AIP
99
Ameritas Investment Partners
Nebraska
$66.8K +$13.7K +851 +20%
Daiwa Securities Group
100
Daiwa Securities Group
Japan
$66K – – –
2 3
4
5 6

VERV Hedge Fund Activity: Q3 2023 in Review

134 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q3 2023, worth a combined $847M — down 27% from $1.16B a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new VERV positions and 14 closed out — a net gain of 13 holders — while 58 added to existing stakes and 24 trimmed.

The largest buyer was Vanguard Group, adding an estimated $11.9M. The largest seller was Avidity Partners Management, cutting an estimated $9.55M.

  • 134 institutional investors held Verve Therapeutics (VERV) as of Q3 2023, up from 121 in Q2 2023.
  • Funds reported $847M of Verve Therapeutics stock for Q3 2023, down 27% quarter-over-quarter.
  • 27 funds opened new Verve Therapeutics positions in Q3 2023 and 14 closed out, a net change of +13 holders.
  • The largest Verve Therapeutics buyer in Q3 2023 was Vanguard Group, an estimated $11.9M added.
  • The largest Verve Therapeutics seller in Q3 2023 was Avidity Partners Management, an estimated $9.55M sold.

Based on aggregated 13F filings for Q3 2023.